LSLobna Shalaby

Lobna Shalaby

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lobna Shalaby has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Satisfaction level of family caregivers of children with cancer towards home care during the coronavirus disease of 2019 (COVID-19) pandemic in Egypt: A cross-sectional study

    by Nora Ahmed Ahmed, Saida Zakaria, Rehan Abdelmaksoud, Ragaa Sayed, Samah Elwy, Manal Mostafa, Sanaa Reda, Ahmed Emad, Ehsan Khaled, Lobna Shalaby

    The coronavirus disease of 2019 (COVID-19) pandemic placed unprecedented pressure on global healthcare systems, prompting the need for innovative strategies to ensure continuity of care. At the Children's Cancer Hospital in Egypt, a home monitoring program was implemented to sustain pediatric oncology care while reducing hospital burden during pandemic surges. The initiative aimed to assess the satisfaction level of family caregivers of children with cancer towards home care during the COVID-19 pandemic in Egypt. In a cross-sectional study, a patient satisfaction survey was administered to a purposive sample of 179 family caregivers (parents) of pediatric oncology patients enrolled in the home monitoring program. One hundred seventy-nine family caregivers of patients with cancer participated in the present study. 53% of the assigned family caregivers were mothers. The Caregivers’ education was secondary technical in 45% of the whole population. The majority of parents were delighted with the nursing care provided to children at home. Satisfaction levels with home care remained very favorable throughout both periods of the COVID-19 pandemic. In the first and second waves of COVID-19, 94.5% of participants reported “excellent” satisfaction and 5.5% reported “reasonable” satisfaction, while in the third and fourth waves of COVID-19, these values were 91.3% and 8.7%, respectively (P=0.541). Overall, the majority of participants reported high satisfaction levels with the home-based nursing care provided. Home-based monitoring proved to be a highly effective and well-received approach to managing pediatric oncology patients during the COVID-19 crisis. It alleviated pressure on hospital resources while preserving quality care and family engagement. This model shows promise for broader application in similar healthcare contexts and during future public health emergencies.

  • Open Access

    Rapid Identification of Carbapenemase Genes Directly from Blood Culture Samples

    by Ghada A. Ziad, Deena Jalal, Mohamed Hashem, Ahmed A. Sayed, Sally Mahfouz, Ahmed Bayoumi, Maryam Lotfi, Omneya Hassanain, May Tolba, Youssef Madney, et al.

    Background/Objectives: The rapid identification of carbapenemase genes directly from positive blood culture (BC) samples shortens the time needed to initiate optimal antimicrobial therapy for Carbapenemase-Producing Enterobacterales (CPE) infections. Several commercial automated PCR systems are available for detecting CPE resistance genes but are expensive. The Xpert® Carba-R assay (Cepheid GeneXpert System) has high sensitivity and specificity for the detection of carbapenamase genes from bacterial colonies or rectal swabs, with an affordable price. This assay was not used for positive BC testing of CPE resistance genes. Whole-Genome Sequencing (WGS) for resistance genes can be used as the gold standard at a research level. In this study, we evaluated the performance of the Xpert® Carba-R assay for the early detection of carbapenamase genes directly from positive BCs, using WGS as the gold standard. Methods: A prospective observational study was conducted at Children’s Cancer Hospital-Egypt (CCHE-57357). All positive BCs underwent direct gram staining and conventional cultures. A total of 590 positive BCs containing Gram-negative rods (GNRs) were identified. The Xpert® Carba-R assay was used to detect carbapenemase genes directly from the positive BC bottle compared with WGS results. Results: Among the 590 GNR specimens, 178 were found to carry carbapenemase genes using the Xpert® Carba-R assay, with results obtained in approximately one hour. The main genotypes detected were blaNDM, blaOXA-48-like, and dual blaNDM/blaOXA-48-like at 27%, 29%, and 33%, respectively. The agreement between Xpert® Carba-R assay and WGS results was almost perfect for the genotype resistance pattern of isolates and individual gene detection. Conclusions: The use of the Xpert® Carba-R assay directly from BC bottles was an easy-to-use, time-saving, affordable tool with high accuracy in identifying carbapenemase genes and, thus, shortens the time needed to initiate optimal antimicrobial therapy for CPE infections.


  • Open Access

    Changes in Gut Microbial Diversity and Correlation with Clinical Outcome in Children with Acute Myeloid Leukemia Receiving Induction Chemotherapy

    by Mai Adel, Reham Abdelaziz Khedr, Ahmed A. Sayed, Lobna Shalaby, Aya A. Diab, Abdelrahman Yahia, Mervat Elanany, Leslie E. Lehmann, Sonia Ahmed, Ramy K. Aziz, et al.

    Background: The gut microbiome affects human health, and patients with cancer are no exception. In those patients, intensive chemotherapy impairs gut barrier integrity, causing dysbiosis, bacterial translocation, and higher infection risk. Objectives: This prospective study, conducted at Children’s Cancer Hospital in Egypt, profiles the microbiome of 29 pediatric patients with AML, and examines how induction chemotherapy and antibiotics affect their microbiome. Methods: Gut microbiome changes were evaluated before treatment (T1), then 7 (T2) and 21–28 days (T3) from induction start. Microbial DNA, extracted from rectal swabs or stool samples, was subjected to 16S rRNA amplicon sequencing, followed by bioinformatics and statistical analyses. Results: Treatment significantly decreased the richness and Shannon diversity of the gut microbiome and caused dysbiosis that was only partially restored at T3. Whereas Firmicutes remained the most abundant phylum throughout, Actinobacteria significantly decreased in abundance after treatment. Proteobacteria had their lowest abundance at T3, while Verrucomicrobacteria were relatively abundant at T1 but undetectable by T3. The abundance of Enterococcus and Klebsiella was associated with stool culture results, and the Proteobacteria-to-Firmicutes ratio was associated with treatment. Conclusions: Gut microbial diversity declined in patients during induction chemotherapy, with a strong association of microbial composition with stool culture results but not with bacteremia.


  • Open Access

    Carbapenem-Resistant Enterobacteriaceae (CRE) in Children with Cancer: The Impact of Rapid Diagnostics and Targeted Colonization Strategies on Improving Outcomes

    by Youssef Madney, Sally Mahfouz, Ahmed Bayoumi, Omayma Hassanain, Omneya Hassanain, Ahmed A. Sayed, Deena Jalal, Maryam Lotfi, May Tolba, Ghada A. Ziad, et al.

    Carbapenem-resistant Enterobacteriaceae (CRE) pose an emerging threat, with a high mortality rate among children with cancer. This study aimed to evaluate the impact of routine rectal swab surveillance and rapid PCR-based detection of carbapenemase genes to facilitate the early initiation of appropriate treatment and assess its effects on outcomes. The study compared two groups of pediatric cancer patients with CRE bloodstream infections: a retrospective cohort of 254 patients from 2013 to 2017, and a prospective cohort of 186 patients from 2020 to 2022, following the implementation of these tools. A rapid diagnostic test in the prospective cohort resulted in the early initiation of proper antibiotics in 85% (165/186) of patients, compared to only 58% (147/254) in the retrospective group. This led to a decrease in the need for ICU admission related to sepsis from CRE and a significant reduction in the 30-day mortality rate (16% vs. 30%, p ≤ 0.01). Genotypic profiling revealed that class B carbapenemases were the most prevalent (69%), with the NDM type being identified in 67% of patients. OXA-48 and KPC enzymes were detected in 59% and 4% of patients, respectively. Multivariate analysis revealed that patients having Klebsiella pneumoniae, NDM genotype carbapenemases, presence of pneumonia, and septic shock requiring ICU admission were predictors of poor outcomes. Rapid diagnostics and targeted colonization lead to the appropriate use of targeted antibiotics, resulting in improved patient outcomes. Understanding carbapenemase-producing microorganisms and administering newer antibiotics may further reduce mortality and enhance treatment strategies for high-risk patients.


  • Open Access

    A Pilot Metabolomic Study for Diagnosing Aspergillus Infection in Immunocompromised Pediatric Cancer Patients

    by Taghreed Khaled Abdelmoneim, Asmaa Ramzy, Mostafa Ahmed Zaki, Ahmed Karam, Ahmed Hesham, Aya Osama, Nabila Sabar, Maha Mokhtar, Nada A. Youssef, Eman A. Ahmed, et al.

    Fungal infection caused by invasive Aspergillus is a life-threatening complication in immunocompromised pediatric cancer patients. However, the early diagnosis of invasive infection remains a clinical challenge due to the lack of specific, non-invasive biomarkers. The current study investigates plasma metabolomic profiling integrated with an AI-derived fungal secondary metabolite database to identify potential biomarkers for rapid, non-invasive detection of Aspergillus infection. Plasma samples from thirteen pediatric oncology patients were analyzed using untargeted metabolomics based on UHPLC-MS/MS. Based on galactomannan assay results, three patients were classified as Aspergillus-Infected (AIC) and ten as non-infected controls (NPCs). An in-house custom database for secondary metabolites of fungi was incorporated to enhance metabolite annotation. Eight metabolites were found to be candidate biomarkers based on statistical significance, fold change, and biological relevance. In the AIC cohort, aflatoxin B1, aspergillimide, fumifungin, and uridine were found to be significantly elevated while citric acid presented a decrease. Multivariate analysis utilizing PCA and PLSDA showed distinct group separation. Moreover, sample size estimation indicates that a minimum of 25 participants would be needed in future studies for appropriate statistical power.


  • Open Access

    Carbapenem-Resistant Enterobacteriaceae (CRE) among Children with Cancer: Predictors of Mortality and Treatment Outcome

    by Youssef Madney, Shaimaa Aboubakr, Reham Khedr, Hanafy Hafez, Naglaa Ahmed, Khaled Elsheshtawy, Mervat Elanany, Abdelhamid Salahelden, Lobna Shalaby, Ola Galal Behairy

    Carbapenem-resistant Enterobacteriaceae (CRE) is an important emerging threat among pediatric cancer patients, with a high mortality rate. This retrospective study included all pediatric cancer patients with (CRE) bloodstream infections (BSIs) at a children’s cancer hospital in Egypt (2013–2017). Two hundred and fifty-four pediatric cancer patients with CRE BSI were identified; 74% had hematological malignancies, and 26% had solid tumors. Acute myeloid leukemia was the most common hematological malignancy (50%). The main clinical features for acquiring CRE-BSI were previous antibiotics exposure (90%), profound neutropenia (84%), prolonged steroid use (45%), previous colonization with a resistant pathogen (35%), ICU admission within 90 days (28%), and central venous catheter use (24%). E. coli was the most common isolated pathogen (56%), followed by Klebsiella pneumoniae (37%). All isolates were resistant to carbapenem with an MIC < 4–8 μg/mL in 100 (45%) and >8 μg/mL in 153 (55%). The overall mortality rate was 57%, and 30 day mortality was reported in 30%. Upon multivariate analysis, for the patients with Klebsiella pneumoniae BSI, carbapenem resistance with an MIC > 8 μg/mL and associated typhlitis or pneumonia were predictors of poor outcome. In conclusion, CRE-BSI is a major threat among pediatric cancer patients in limited resource countries with limited options for treatment. Antimicrobial stewardship for early detection through routine screening, adequate empirical treatment, and timely adequate therapy may impact the outcome for such high-risk patient groups.